Latest News

• Dr. Steven Brem joins the Musella Foundation as Chief Scientific Advisor!        

  The Musella Foundation is honored to welcome Dr. Steven Brem as its Chief Scientific Advisor. Dr. Brem is a world-renowned neurosurgeon, educator, and innovator in the field of brain tumor research and care. He currently serves as Professor and Director of Medical Student Education in the Department of Neurosurgery, Medical Director of the Center for Precision Surgery, and Senior Member of the Penn Brain Tumor Center. For the full press release, please visit HERE. 

  
  
• Upcoming webinar!        

  Mark your calendars! Our next webinar is coming up on Thursday, September 18 at 7pm ET with Dr. Karisa Schreck on "BRAF-Targeted Therapies for Brain Tumors"!

  
  
• The 6th Annual Mark Salkowski 5k Run/Walk        

  The 6th Annual Mark Salkowski 5K Run/Walk will be held on Sunday, September 14, 2025, at the Falling Branch Brewery in Street, MD. All proceeds benefit brain cancer research conducted by the Musella Foundation. Mark was a loving father, husband, brother, and friend to many. He sadly passed away from glioblastoma, a rare and deadly form of brain cancer, on December 28, 2015. This event is to honor Mark and raise funds in his name to support the fight against brain cancer. Registration begins at 8:00 with the run/walk starting at 9:00. After the event there will be a silent auction, music, and food available and beer for those over 21 years of age. Come out and join us for a great cause and to honor a great man. Questions can be directed to Neil Salkowski at neilsal@aol.com. More information is available and to register or donate, please go to: Musella Foundation: 6th Annual Mark Salkowski Memorial 5K and 1K Fun Run. 

  
  
• Carmustine Wafers (Gliadel) in Brain Metastases: Revisiting an Old Concept with New Insights        

  This single-institution retrospective study reviewed outcomes in 63 patients who underwent surgery for brain metastases, comparing those who received carmustine (BCNU) wafers at the time of resection to those who did not. Lung cancer was the most common primary cancer in the cohort. Progression-free survival (PFS) was significantly improved in the BCNU group versus the surgery-only group. Median overall survival from the time of surgery was 10 months with BCNU versus 7 months without, a difference that did not reach statistical significance. This is the largest modern, two-arm study of BCNU wafers in brain metastases, and it supports their potential to improve local control when used alongside surgery.  

  
  
• PNOC Foundation Launches $50 Million "Lose No Child" Campaign to Transform the Future of Treatment for Kids with Brain Cancer        

  The Pediatric Neuro-Oncology Consortium (PNOC), a global network of over 300 researchers across 43 institutions, has launched the Lose No Child campaign—a $50 million initiative to fast-track safer, more effective treatments for children with brain cancer. The PNOC Foundation aims to cut development timelines in half by funding clinical trials, expanding access to innovative therapies, and advancing AI-driven research. Learn more at: www.losenochild.org.

  
  
• 5th Gliomatosis Cerebri Conference        

  The 5th International Gliomatosis Cerebri (GC) Conference will be held in London on September 17-19. This conference builds on the success of earlier meetings in Paris, Bethesda, Barcelona and New York City and aims to bring together clinicians, researchers and families to hear about the latest research in GC and discuss ways to make progress for this disease. The event is invitation only; if interested in attending, please contact Chris Jones, PhD, Institute of Cancer Research at chris.jones@icr.ac.uk.